Shares of KemPharm, Inc. (NASDAQ:KMPH) have earned an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $9.00.

Several equities research analysts have weighed in on the company. ValuEngine cut KemPharm from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Canaccord Genuity set a $7.00 target price on KemPharm and gave the stock a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $13.00 target price on KemPharm and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, Roth Capital assumed coverage on KemPharm in a report on Wednesday, June 28th. They issued a “buy” rating and a $8.00 target price for the company.

In related news, major shareholder Delaware Street Capital Master acquired 325,888 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was purchased at an average cost of $3.27 per share, for a total transaction of $1,065,653.76. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Travis C. Mickle acquired 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average price of $3.45 per share, with a total value of $27,600.00. Following the completion of the purchase, the chief executive officer now directly owns 1,629,612 shares in the company, valued at $5,622,161.40. The disclosure for this purchase can be found here. Insiders have purchased a total of 343,163 shares of company stock valued at $1,117,461 over the last 90 days. 22.80% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its stake in shares of KemPharm by 17.6% during the 1st quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after purchasing an additional 3,414 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of KemPharm during the 1st quarter worth $647,000. Finally, C WorldWide Group Holding A S lifted its stake in shares of KemPharm by 110.1% during the 2nd quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock worth $1,527,000 after purchasing an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 40.01% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “KemPharm, Inc. (KMPH) Given Average Rating of “Buy” by Brokerages” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/16/kempharm-inc-kmph-given-average-rating-of-buy-by-brokerages.html.

KemPharm (KMPH) opened at 3.55 on Friday. KemPharm has a 12 month low of $2.45 and a 12 month high of $5.40. The stock’s market cap is $52.03 million. The firm’s 50-day moving average price is $3.07 and its 200 day moving average price is $3.80.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.19. On average, analysts anticipate that KemPharm will post ($2.72) earnings per share for the current year.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.